Clearmind Medicine Inc. — FY2023 Form 20-F
Reporting period: Fiscal year ended October 31, 2023; filed January 29, 2024. The company reports under IFRS in U.S. dollars. This is an annual report, not a standalone fourth-quarter report.
Business context
Clearmind is a pre-revenue, clinical-stage pharmaceutical company developing psychedelic-based treatments. Its lead candidate, MEAI (CMND-100), is being developed principally for alcohol use disorder (AUD); the company also describes exploratory work in obesity and metabolic disorders and other indications. It has no approved products and has never generated product-sales revenue.
Financial results and liquidity
| Metric (USD) | FY2023 | FY2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $1.544 million | $3.081 million |
| General and administrative expense | $4.759 million | $3.170 million |
| Total operating expenses | $6.303 million | $6.251 million |
| Net loss | $8.621 million | $6.895 million |
| Net cash used in operating activities | $6.301 million | $3.724 million |
| Net cash provided by financing activities | $11.664 million | $0.512 million |
- R&D expense fell 50%, mainly as preclinical-study spending declined. G&A rose 50%, reflecting higher professional fees, investor-relations costs and directors’ and officers’ insurance.
- Net loss increased 25%. A $2.190 million loss from revaluing derivative warrant liabilities was a significant unusual non-cash finance item; the company also recorded a $107,638 unrealized loss on its short-term investment.
- At year-end, cash and cash equivalents were $5.428 million, short-term investments $86,112 and restricted cash $37,675. Working capital was positive $824,760, compared with negative $1.498 million a year earlier. Accounts payable and accrued liabilities were $617,004; amounts due to related parties were $42,433.
- Total liabilities were $4.970 million, including $4.310 million in derivative warrant liabilities. The company reported no long-term liabilities at October 31, 2023; it subsequently renewed its office lease at approximately $6,500 per month through June 2025.
- Operating cash use increased 69% year over year, while financing proceeds from share and warrant offerings supported the increase in cash. No gross margin or product profitability is reported because the company has no product sales.
Material developments and outlook
- The company submitted an IND application to the FDA in March 2023 for its first-in-human Phase I/IIa CMND-100 study, and reported starting the multinational study in May 2023 after also submitting an application to Israeli authorities. The filing describes a study of safety, tolerability and pharmacokinetics, with preliminary AUD-related measures. However, it also says FDA authorization was awaited and elsewhere says enrollment had not commenced; the precise regulatory and enrollment status is therefore unclear in the filing text.
- Management expects research and development and public-company costs to increase, anticipates continued losses, and says additional financing will be needed. It provides no quantified revenue, earnings or cash-flow guidance and does not state a clear cash-runway estimate.
- FY2023 operating cash use was $6.301 million. Subsequent financing included a January 2024 offering with $2.4 million gross proceeds and approximately $2.0 million net proceeds. The filing also reports post-year-end warrant exercises; future capital needs and dilution remain important considerations.
- The audited financial statements include a going-concern explanatory paragraph: accumulated losses, no revenue and negative operating cash flow create substantial doubt about the company’s ability to continue as a going concern. The statements contain no adjustments for a possible failure to continue as a going concern.
- Preclinical findings are not proof of human safety or efficacy. The filing reports adverse effects and mortality at some higher MEAI doses in animal studies, and describes controlled-substance, regulatory, manufacturing, trial-enrollment, competition and reimbursement risks. MEAI is considered controlled in Israel; its U.S. scheduling is unresolved, and Health Canada has described it as controlled based on structural similarity.
- The company reported no material legal proceedings. It disclosed material weaknesses in internal financial controls and concluded that disclosure controls and internal control over financial reporting were ineffective at year-end. Remediation was underway; the auditor did not attest to internal-control effectiveness.
- Operations and trial infrastructure are concentrated partly in Israel. The company said it had not experienced war-related operational disruption as of the filing’s stated update, but warned that conflict could affect staff, service providers, trials and supply. It also disclosed related-party links and collaborations involving SciSparc.
Important facts for investors to verify
- Confirm the IND decision, Israeli approvals, actual enrollment, trial progress and any safety updates for CMND-100.
- Review the going-concern note and assess cash runway against operating cash use, planned development spending and financing availability.
- Check warrant terms, derivative-liability valuation and subsequent exercises or repricing, as these affect reported earnings, potential dilution and future cash proceeds.
- Track remediation of internal-control weaknesses and any later management or auditor assessment of their effectiveness.
- Assess the status and scope of MEAI’s controlled-substance classification across jurisdictions, and the maturity and ownership of the company’s patent portfolio.